Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top

12-04-2024 | Alzheimer's Disease | Panel Discussion | Article | Lilly

Experts in Conversation

Implementing AD biomarkers and amyloid-targeting therapies

Login to get access

Dorota Religa and Robert Perneczky walk us through the most exciting findings from the AD/PD™ and CONy 2024 conferences. Their discussion focuses on existing and emerging biomarkers and new amyloid-targeting therapies in Alzheimer's disease. 

Related topics

Dementia rotated-square
Neurology rotated-square
Biomarkers rotated-square
Geriatrics and Gerontology rotated-square
AD/PD™ 2024 rotated-square
CONy 2024 Congress rotated-square
Image Credits